Should You Consider Retaining ZBH Stock in Your Portfolio Now?
Zimmer Biomet's robust efforts to expand the Knee business and a gradually stabilizing musculoskeletal market appear promising.
Zimmer Biomet: Back On Offense With Strong Cash Flow Outlook
Zimmer Biomet Holdings (ZBH) is expanding its product portfolio and improving cash flow, positioning it for long-term profitability and financial health. ZBH is undervalued compared to peers, with significant growth potential driven by innovation, acquisitions, and operational efficiency improvements. The company's focus on high-growth markets and improving profitability metrics indicate a strong future outlook, despite past underperformance.
ZBH Stock to Benefit From Global Expansion Despite Macro Issues
Zimmer Biomet is witnessing strong market share gains within reconstructive Knees and Hips in key geographies despite macroeconomic challenges.
ZBH Stock Might Rise Following FDA Nod for OsseoFit
Zimmer Biomet's OsseoFit Stemless Shoulder System gets FDA 510(k) approval. The company expects to launch the system in the first quarter of 2025.
Reasons to Retain ZBH Stock in Your Portfolio for Now
Zimmer Biomet's robust efforts to expand market share and a gradually stabilizing musculoskeletal market appear promising.
ZBH Stock Might Rise Following FDA Nod for Knee Implant Component
Zimmer Biomet's Persona SoluTion Porous Plasma Spray Femur gets FDA 510(k) approval. The company expects to launch the system in the first quarter of 2025.
Why Is Zimmer (ZBH) Up 4.8% Since Last Earnings Report?
Zimmer (ZBH) reported earnings 30 days ago. What's next for the stock?
ZBH Stock Gains From FDA Nod for Oxford Cementless Partial Knee
Zimmer Biomet receives FDA nod for the Oxford Cementless Partial Knee. It is a PMA Supplement approval.
ZBH Stock Gains From Receiving CE Mark for Persona Revision Knee System
Zimmer Biomet gets CE Mark Certification for Persona Revision Knee System, followed by the successful introduction in the United States and other markets.
ZBH Stock to Gain Support From Market Share Gains Amid Macro Issues
Zimmer Biomet expects ROSA and Persona Cementless Knee to enhance its robotics and cementless market penetration to 50% to 60% range at a rapid pace.
Orthopedic Implant Maker Zimmer Biomet Reports Better-Than-Expected Q3 Earnings, Updates Annual Forecasts
On Wednesday, Zimmer Biomet Holdings, Inc ZBH reported third-quarter adjusted EPS of $1.74, up from $1.65 a year ago, in line with the Street estimates.
ZBH Stock Up Despite Q3 Earnings Miss, 2024 View Narrowed
Zimmer Biomet delivers strong performance across segments and regions in the third quarter of 2024.
